VARIAR Study: Assessment of Short-term Efficacy and Safety of Rituximab Compared to an Tumor Necrosis Factor Alpha Antagonists as Second-line Drug Therapy in Patients With Rheumatoid Arthritis Refractory to a First Tumor Necrosis Factor Alpha Antagonist Vicenç Torrente-Segarra, Asunción Acosta Pereira, Rosa Morla, José Miguel Ruiz, Teresa Clavaguera, Ramon Figuls, Hector Corominas, Carme Geli, Rosa Roselló, Juan José de Agustín, Cayetano Alegre, Carolina Pérez, Angel García, Arturo Rodríguez de la Serna

Skin Lesions and Treatment With Tumor Necrosis Factor Alpha Antagonists Maria Victoria Hernández, Melina Meineri, Raimon Sanmartí

How many patients with rheumatic diseases and TNF inhibitors treatment have latent tuberculosis? Noemi Busquets-Pérez, Andrés Ponce, Vera Ortiz-Santamaria, Juanjosé de Agustín de Oro, Yolanda León Hernández-Rico, Imma Vidal, Carolina Alfonso, Sonia Argemí, Blanca Muñoz, Fernando Quispe, Ana Carolina Díaz, Salvador Campos, Teresa Mariné Hernández, Miquel Torres, Xavier Surís